Determinación de la mutación BRAF V600E en melanomas de pacientes uruguayos

Mazzei, María Eugenia; Hochmann, Jimena; Manrique, Gonzalo; Mariño, Ana Luisa; Delgado, Lucía; Martínez Asuaga, Miguel.
Rev. méd. Urug ; 29(2): 97-102, 2013. ilus
Artículo en Español | URUCAN | ID: bcc-4660

Documentos relacionados

  1. Metabolic Lipids in Melanoma Enable Rapid Determination of Actionable BRAF-V600E Mutation with Picosecond Infrared Laser Mass Spectrometry in 10 s.
  2. Melanoma: BRAFi Rechallenge.
  3. Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect.
  4. BRAF Immunoexpression Can Be Intralesionally Heterogeneous but BRAF V600E Mutation Status Is Intralesionally Homogeneous and Interlesionally Concordant in Melanoma: A Study of 140 Lesions From 98 Patients.
  5. BRAF V600E mutation as a prognostic factor in cutaneous melanoma patients.
  6. The association between BRAF-V600E mutations and death from thin (≤1.00 mm) melanomas: A nested case-case study from Queensland, Australia.
  7. Alpha-melanocyte stimulating hormone (α-MSH): biology, clinical relevance and implication in melanoma.
  8. Co-existence of BRAF V600E-mutated malignant melanoma and BRAF V600E-mutated Langerhans cell histiocytosis: A case report.
  9. Histopathologic and molecular characterization of BAP-1-inactivated melanoma.
  10. BRAFV600E Expression Is Homogenous and Associated with Nonrecurrent Disease and Better Survival in Primary Melanoma.